BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

Shots: The P-III EXPLORER-HCM study involves assessing Mavacamten vs PBO in 251 patients in a ratio (1:1) with symptomatic oHCM (LVOT gradient ≥50 mmHg and NYHA Class II-III) for 30wks, followed by an 8-week washout Results: @30wks. change in KCCQ OSS in greater than PBO arm; KCCQ OSS ≥20 points (36% vs 15%); a greater …

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021 Read More »